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Abstract
Background: In this study, porcine encephalomyocarditis virus (EMCV) virus-like particles (VLPs) were generated
using a baculovirus expression system and were tested for immunogenicity and protective efficacy in vivo.
Results: VLPs were successfully generated from Sf9 cells infected with recombinant baculovirus and were
confirmed to be approximately 30-40 nm by transmission electron microscopy (TEM). Immunization of mice with
0.5 μg crude protein containing the VLPs resulted in significant protection from EMCV infection (90%). In swine,
increased neutralizing antibody titers were observed following twice immunization with 2.0 μg crude protein
containing VLPs. In addition, high levels of neutralizing antibodies (from 64 to 512 fold) were maintained during a
test period following the second immunization. No severe injection site reactions were observed after
immunization and all swine were healthy during the immunization period
Conclusion: Recombinant EMCV VLPs could represent a new vaccine candidate to protect against EMCV infection
in pig farms.
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Background
The porcine encephalomyocarditis virus (EMCV) is a
member of the genus Cardiovirus of the family Picorna-
viridae, the genome is a single-stranded positive sense
RNA of approximately 7.8 kb with a unique large open
reading frame (ORF) [1]. Porcine EMCV infection,
which is characterized by acute myocarditis and sudden
death in preweaned piglets and severe reproductive fail-
ure in sows, results in severe economic losses for swine
production [2-4].
An inactivated EMCV vaccine is considered as one of
the effective strategies for preventing EMCV infection in
domestic and wild animals [5,6]. Recently, vaccination
with porcine EMCV virus-like particles (VLPs) has also
been examined as a novel candidate for protection
against porcine EMCV [7]. However, VLP-based vac-
cines against porcine EMCV produced using a baculo-
virus system have not yet been developed.
One of the most important technological develop-
ments to emerge from the baculovirus expression sys-
tem was the observation that the expression of viral
capsid proteins could lead to the assembly of VLPs that
mimic the overall structure of authentic viral particles
but are devoid of viral nucleic acids [8]. VLPs represent
a highly effective alternative vaccine strategy. They have
been shown to stimulate B-cell-mediated immune
responses, and are also highly effective at stimulating
CD4 proliferative responses and cytotoxic T-lymphocyte
(CTL) responses [9-11]. VLPs have thus been developed
as novel vaccine candidate for many kinds of viruses
including bluetongue virus [12], rabbit hemorrhagic dis-
ease virus [13], severe acute respiratory syndrome
(SARS) virus [14], Norwalk-like viruses [15], and parvo-
virus [16]. Moreover, hepatitis B virus (Recombivax HB,
Merck) and human papillomavirus (Gardasil
®, Merck)
VLPs have been approved for use as vaccines.
In this study, we generated a recombinant baculovirus
Bac-P12A3C, which contains the structural protein P1,
the nonstructural protein2 Aa n dt h ep r o t e a s e3 Co f
porcine EMCV K3 (wild strain) to induce formation of
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porcine EMCV particles. We then evaluated the protec-
tive immune response induced by the recombinant
VLPs in mice and their immunogenicity in swine.
2. Materials and methods
2.1. Viruses, cells and antibodies
The Korean porcine EMCV K3 strain (pEMCV-K3) iso-
lated in 1990 and the monoclonal antibody (MAb) 3F10
against the VP1 protein of pEMCV-K3 were used as
described previously [7]. The Spodoptera frugiperda
( S f 9 )i n s e c tc e l l sw e r em a intained in Grace medium
(Invitrogen, USA) containing 5% fetal bovine serum
(Gibco, USA), lactalbumin hydrolysate (Gibco, USA),
and an antibiotics-antimycotic solution (Gibco, USA) at
27°C, and infected Sf9 cells were maintained in Sf 900 II
SFM (Gibco, USA) without fetal bovine serum.
2.2. Construction of recombinant baculovirus transfer
vectors and generation of recombinant baculovirus
Genes of the capsid protein P1, the nonstructural protein
2A and the protease 3C of pEMCV-K3 were amplified
and cloned into a pFastBac™ HTB (Invitrogen, USA) as
described previously [7]. The P12A3C gene was then
inserted down stream of the polyhedron promoter (PPH).
Recombinant baculovirus was generated by site-specific
transposition of pFastBac/P12A3C into a baculovirus
shuttle vector (bacmid) propagated in DH10Bac cells
(Invitrogen, USA) by using the Bac to Bac baculovirus
expression system (Invitrogen, USA) according to the
manufacturer’s instructions. Recombinant baculovirus
(Bac-P12A3C) was plaque purified, and then the presence
of the P12A and 3C genes of pEMCV-K3 was confirmed
by PCR using previously described primer sets [7].
2.3. Expression of recombinant proteins
Sf9 cells in 6-well culture plates were infected with
recombinant baculovirus at a multiplicity of infection
(MOI) of 10 for 72 h. Vero cells were infected with
pEMCV-K3 grown in 6-well culture plates (as a positive
control). The expressed recombinant proteins were ana-
lyzed by immunofluorescence assay (IFA) and Western
blotting analysis as previously described [7].
2.4. Morphology of VLPs
Sf9 cells in 25 cm
2 flasks were infected with recombinant
baculovirus at an MOI of 10 and harvested at 4 day
post-infection (dpi). The harvested cells were clarified by
centrifugation, concentrated using polyethylene glycol
precipitation and then, loaded onto a 20-60% (w/v) dis-
continuous sucrose step density gradient as described
previously [7]. The peak fraction from the sucrose gradi-
ent was allowed to settle on glow-discharged carbon-
coated grids for morphological examination by transmis-
sion electron microscopy (TEM, Tecnai G2) at the Korea
Basic Science Institute. The grid was blotted dry, and
stained with 1% uranyl acetate. The sample was
visualized using a transmission electron microscope at
60,000 × magnification.
2.5. Animal experiments
2.5.1 Efficacy of EMCV VLPs in mice Female BALB/c
mice (aged 6-8 weeks) were used for the immunization
and challenge trials. The mice were randomly divided
into four groups, with fifteen mice in each group. All
groups were intramuscularly (I.M) inoculated with 0.1
ml antigen two times at an interval of 2 weeks. Group 1
was inoculated with PBS as a negative control, and
Group 2 was inoculated with a commercial killed vac-
cine (Choongang Vaccine Laboratory, Korea) as a posi-
tive control. Group 3 and Group 4 were inoculated with
0.5 μga n d0 . 1μg respectively, of crude protein extract
from Bac-P12A3C infected cells containing VLPs. On 14
day post-vaccination, ten mice in each group were chal-
lenged intramuscularly with 0.1 ml of the pEMCV-K3
strain containing 10
6 TCID50/ml (1000MLD50/ml) per
mouse. The remainder in each group was analyzed for
humoral immune response as described previous [17].
2.5.2 Safety and Immunization in swine Twelve pigs,
weighing approximately 30-40 kg each, that were anti-
body - negative against EMCV were separated into six
groups of two pigs each. Antigen was mixed with an
e q u a lv o l u m eo fa nM o n t a n d i d eI M S1 3 1 3 ™ NV G
(Seppic, France), and all groups were inoculated intra-
muscularly with 1.0 ml antigen-adjuvant mixture. Group
1 was inoculated with PBS as a negative control, and
Group 2 was inoculated with commercial vaccine as a
positive control. Group 3 and Group 5 were inoculated
once each with 2.0 μga n d0 . 2μg of crude protein,
respectively, which was extracted from Bac-P12A3C
infected cells containing VLPs. Group 4 and Group 6
were inoculated twice in a 2 week interval with 2.0 μg
and 0.2 μg respectively, of crude protein extracted from
Bac-P12A3C infected cells containing VLPs. After each
immunization, all swine were observed for 30 min and
monitored for clinical signs during the immunization
period at 2 day intervals. Sera were collected every week
for 50 days from immunized swine to analyze serocon-
version. Neutralizing EMCV antibodies were detected in
collected sera using an in vitro neutralization assay as
described previous [17].
2.6. Statistics analysis
Results of neutralizing antibodies levels were presented
as the means ± SEM. The significance of the variability
among the experimental groups was determined by two-
way ANOVA. A probability value (P) of < 0.05 was con-
sidered significant.
3. Results
3.1. Expression and identification of VLPs in vitro
Sf9 cells were transfected with a bacmid contained the
P12A and 3C genes, and recombinant baculoviruses
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confirmed by PCR (data not shown). Cells were infected
with Bac-P12A3C at an MOI of 10, and cells and super-
natants were harvested and analyzed at 3 dpi, at which
point most of the cells showed cytopathic effects (CPE).
In the IFA, Sf9 cells infected with Bac-P12A3C reacted
with the Mab 3F10 and exhibited strong cytoplasmic
staining (Figure 1A). Western blotting showed that a
specific protein of the predicted size of 30 kDa (VP1)
was observed in both Vero cells with the pEMCV-K3
strain and in Sf9 cells infected with Bac-P12A3C
(Figure 1B).
3.2. Analysis of VLP morphology
To examine whether cells infected with Bac-P12A3C
can generate virus-like particles, Sf9 cells infected with
Bac-P12A3C were prepared for visualization by TEM.
As seen in Figure 2, hollow spherically shaped structures
with a diameter of about 30 nm were identified in Bac-
P12A3C-infected cells, whereas no such structures were
observed in uninfected Sf 9 cells (data not shown).
3.3. Seroconversion and protection of immunized mice
Serum samples were collected from each immunized
mouse group on day 14 after the second immunization.
The negative control group immunized with the PBS
(Group 1) was negative for pEMCV-K3 neutralizing
antibodies, whereas Group 2, which was immunized
with a commercial vaccine, produced virus-neutralizing
antibodies at high levels (from 256 to 1,024 fold). Group
3 and Group 4, which were immunized with 0.5 μga n d
0.1 μg, respectively, of crude protein containing VLPs,
exhibited virus-neutralizing antibodies (from 128 to
1,024 fold for Group3, and from 64 to 512 fold for
Group 4). In each challenged group, all ten mice immu-
nized with the commercial vaccine were protected
perfectly, whereas mice immunized with the PBS all
died due to infection within 3 to 4 days post-challenge.
Nine of the ten mice immunized with 0.5 μgo fc r u d e
protein containing VLPs were protected to a high level,
but only 60% of the mice immunized with 0.1 μgo f
crude protein containing VLPs survived (Figure 3).
3.4. Safety and immunity in swine
As seen in Figure 4 determined by two-way ANOVA,
neutralizing antibodies in the pigs of Group 3 were
increased 128 fold and those of Group 5 were increased
64 fold upon inoculation with a single dose of crude
protein containing VLPs. Steady production of the anti-
bodies was maintained for two weeks, but decreased
dramatically three weeks after immunization (from 4 to
8 fold). Group 4 and Group 6 showed an increased pro-
duction of neutralizing antibodies after the primary and
secondary inoculation with crude protein containing
VLPs, and these neutralizing antibody levels were main-
tained at high levels for up to 5 weeks after the last
inoculation. The level of neutralizing antibodies in
Group 4 (from 64 to 512 fold) was similar to that of
group 2. On Group 2, swine immunized with the
commercial EMCV vaccine generated higher levels of
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Figure 1 Analysis of recombinant baculovirus expression using
the monoclonal antibody 3F10, which recognizes an epitope
of the VP1 protein. (A) Expression and intracellular localization of
recombinant baculovirus Bac-P12A3C as identified by
immunofluorescence. (B) Western blotting analyses of recombinant
baculovirus. Lane M, protein molecular weight marker; Lane 1,
whole virus; Lane 2, Sf9 cells infected with Bac-P12A3C.
50nm
Figure 2 Characterization of VLPs using transmission electron
microscopy (TEM). TEM images of Sf9 cells infected with Bac-
P12A3C. The arrows indicate aggregation of VLPs. Bar size: 50 nm
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Figure 3 Protection of immunized mice against a lethal EMCV
challenge. The survival curve was based on the number of mice
surviving on various days post-challenge.
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to 1,024 fold, and these levels of neutralizing antibodies
were maintained until five weeks after final inoculation.
In contrast, swine in Group 1 did not produce any
detectable neutralizing antibodies. No severe injection
site reactions were observed after immunization and all
swine were healthy during the immunization period.
4. Discussion
Virus-like particles are promising vaccine candidates for
triggering neutralizing antibody response since they can
authentically mimic the viral surface and are antigenicity
similar to the parental virus. In addition, they are safely
devoid of infectious genetic material [8,18]. VLPs have
been produced extensively as human and veterinary vac-
cine candidates due to their strong immunogenicity.
The baculovirus expression system has been widely used
for generation of these VLPs due to the high productiv-
ity of the system and the ability to achieve rapid produc-
tion scale implementation [19]. VLPs have been
successfully generated from many other Picornaviridae
family members, including enterovirus [20], poliovirus
[21] and foot-and mouth disease virus (FMDV) [22].
In a previous study, we engineered a DNA vaccine
that produced pEMCV-K3 VLPs and confirmed that the
VLP antigen exhibited good antigenicity and protective
immunity in mice [7]. In the present study, we used a
baculovirus expression system to generate EMCV VLPs,
verified that Bac-P12A3C is capable of expressing a
fusion protein, and confirmed P1 protein is correctly
processed by the 3C protease into the VP1 protein
(approximately 30 kDa) as previously demonstrated
[7,23]. These data also showed that Bac-P12A3C has the
ability to self-assemble into 30 nm to 40 nm VLPs with
a similar morphology to authentic virus particles of por-
cine EMCV showed by TEM [7,20,22,24].
Mice immunized with 0.1 μg of crude protein contain-
ing VLPs (60%), 0.5 μg crude protein containing VLPs
(90%), or the commercial vaccine (100%) displayed dif-
ferent levels of protection in viral challenge experiments.
Correspondingly, a linear relationship between the levels
of neutralizing antibody and the protective efficacy of
EMCV vaccines against lethal EMCV challenge has been
demonstrated [7,23]. VLP-based vaccines have been
s h o w nt oc o n f e rp r o t e c t i o ni na n i m a lm o d e l sa g a i n s t
many viral challenges (i.e., enterovirus [25], foot and
mouth disease virus [26], influenza virus [27] parvovirus
[16], human immunodeficiency [28] and rotavirus [29].
Together, these findings indicate that VLPs can be dra-
matically effective immunogens [8].
To assess the safety of the VLP, two doses of crude
protein including VLPs were tested, with the higher dose
(2.0 μg) 10-fold higher than the lower dose (0.2 μg). No
immunization related clinical signs were observed in any
group. After the second immunization, the levels of neu-
tralizing antibodies were similar to those obtained with
the commercial vaccine and were more effective than sin-
gle-dose immunization in inducing the production and
maintenance of neutralizing antibodies in swine. The
twice immunization were more effective in inducing the
production and maintenance of neutralizing antibodies in
swine than primary immunization. Correspondingly, the
conventional inactivated vaccine is also administered
twice, as the second boost is needed to effectively induce
neutralizing antibody [30]. The production of neutraliz-
ing antibodies has been correlated with protection
against viral infection and is an important feature of an
effective vaccine. In addition, some data suggest that the
induction of high level of EMCV specific neutralizing
antibodies may be essential for protection against EMCV
infection [5,30,31]. This study demonstrates that twice
immunizations with a VLP vaccine can effectively induce
neutralizing antibodies. Thus, this approach may have
significant application as a novel vaccine strategy to con-
trol EMCV. In future studies, we plan to investigate this
VLP vaccine for efficiency, safety, and effects on litter
size in pregnant swine.
Based on the results presented on this study, we con-
clude that porcine EMCV VLPs generated using a bacu-
lovirus expression system are safe and demonstrate
good antigenicity and immunogenicity. The antigenicity
from vaccination against EMCV with these VLP indicate
such systems have as promising vaccines for this disease.
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